GeneDx Surges Past Q2 Expectations,
Sets Up for Strong Year-End Growth
GeneDx delivered a strong Q2 2025, with revenues and earnings beating expectations and full-year guidance raised over 10%.Revenue growth is driven by higher testing volumes, improved reimbursement rates, and a
admin